Wednesday, April 13th, 2016

Companies discussed in this research report are 2-BBB Medicines BV, AB Science SA, Aestus Therapeutics, Inc., Anavex Life Sciences Corp., Angion Biomedica Corp., Apodemus AB, Apogenix GmbH, Apotex, Inc., ArmaGen,Inc., BioCrea GmbH, Biogen, Inc., BrainStorm Cell Therapeutics Inc., CalAsia Pharmaceuticals, Inc., Calico LLC, Catabasis Pharmaceuticals, Inc., Cellceutix Corporation, Chronos Therapeutics Limited, Cytokinetics, Inc., Daval International Limited, Edison Pharmaceuticals, Inc., Eisai Co., Ltd., Evotec AG, F. Hoffmann-La Roche Ltd., Genervon Biopharmaceuticals, LLC, GeNeuro SA, GenKyoTex S.A., GlaxoSmithKline Plc, Glialogix, Inc., Grifols, S.A., Herantis Pharma Plc, ImStar Therapeutics Inc., IntelliCell BioSciences Inc., Isis Pharmaceuticals, Inc., Jeil Pharmaceutical Co., Ltd., Kadimastem Ltd., Karyopharm Therapeutics, Inc., KineMed, Inc., Kringle Pharma, Inc., Kyorin Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Lascco SA, Lead Discovery Center GmbH, Maas Biolab, Mallinckrodt Plc, miCure Therapeutics Ltd., miRagen Therapeutics, Inc., MitoDys Therapeutics Limited, Mitsubishi Tanabe Pharma Corporation, Neuralstem, Inc., Neuraltus Pharmaceuticals, Inc., Neurimmune Holding AG, Neurodyn Inc., Neurotec Pharma SL, Neurotune AG, Nexgenix Pharmaceuticals, LLC, Orion Oyj, Orphazyme ApS, Oxford BioMedica Plc, Pharnext SAS, Primary Peptides, Inc., ProMIS Neurosciences Inc., Q Therapeutics, Inc., ReceptoPharm, Inc., Regenesance BV, reMYND NV, RhinoCyte, Inc., RXi Pharmaceuticals Corporation, Saneron CCEL Therapeutics, Inc., SciFluor Life Sciences, LLC, SK Biopharmaceuticals Co., Ltd., Spherium Biomed S.L., Teva Pharmaceutical Industries Limited, Treeway BV, UCB S.A., uniQure N.V., Valeant Pharmaceuticals International, Inc., Varinel, Inc., ViroMed Co., Ltd., Voyager Therapeutics, Inc. and Yooyoung Pharmaceutical Co., Ltd.

Get discount on this research report at

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

This report provides comprehensive information on the therapeutic development for Amyotrophic Lateral Sclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Amyotrophic Lateral Sclerosis and special features on late-stage and discontinued projects.

Complete research report of 498 pages with TOC is available at


  • The report provides a snapshot of the global therapeutic landscape of Amyotrophic Lateral Sclerosis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Amyotrophic Lateral Sclerosis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Amyotrophic Lateral Sclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Amyotrophic Lateral Sclerosis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Amyotrophic Lateral Sclerosis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Amyotrophic Lateral Sclerosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

File Library

Contact Profile

ReportsnReports is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Connect With Us on:  



Twitter: https: //

G+ / Google Plus:



Ritesh Tiwari
P: + 1 888 391 5441


Amyotrophic Lateral Sclerosis,Amyotrophic Lateral Sclerosis market,Amyotrophic Lateral Sclerosis pipeline,Amyotrophic Lateral Sclerosis market 2015,Amyotrophic Lateral Sclerosis pipeline 2015




More Formats

View QR Code